

## ADULT-ONSET IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM — A TREATABLE FORM OF MALE INFERTILITY

LISA B. NACHTIGALL, M.D., PAUL A. BOEPPLE, M.D., FRANÇOIS P. PRALONG, M.D., AND WILLIAM F. CROWLEY, JR., M.D.

### ABSTRACT

**Background** Men with isolated gonadotropin-releasing hormone (GnRH) deficiency typically present with an absence of pubertal development. We describe an adult-onset form of idiopathic hypogonadotropic hypogonadism that develops after puberty.

**Methods** We studied 10 men (age, 27 to 57 years) with normal sexual maturation, idiopathic infertility, sexual dysfunction, low serum testosterone concentrations, and apulsatile secretion of luteinizing hormone on frequent blood sampling. All the men had otherwise normal anterior pituitary hormone secretion and sellar anatomy. We compared the results of semen analyses and measurements of testicular volume, serum testosterone, inhibin B, and gonadotropins in these men with the results in 24 men with classic GnRH deficiency before and during GnRH-replacement therapy and in 29 normal men of similar age.

**Results** Serum gonadotropin concentrations in the men with adult-onset GnRH deficiency were similar before and during pulsatile GnRH administration to those in the men with classic GnRH deficiency. However, as compared with men with classic GnRH deficiency, men with adult-onset hypogonadotropic hypogonadism had larger mean ( $\pm$ SD) testicular volumes ( $18\pm 5$  vs.  $3\pm 2$  ml,  $P<0.001$ ), serum testosterone concentrations ( $78\pm 34$  vs.  $49\pm 20$  ng per deciliter [ $2.7\pm 1.2$  vs.  $1.7\pm 0.7$  nmol per liter],  $P=0.004$ ), and serum inhibin B concentrations ( $119\pm 52$  vs.  $60\pm 21$  pg per milliliter,  $P<0.001$ ). Treatment with GnRH reversed the hypogonadism and restored fertility in each of the five men who received long-term therapy.

**Conclusions** The recognition of adult-onset hypogonadotropic hypogonadism in men as a distinct disorder expands the spectrum of GnRH deficiency and identifies a treatable form of male infertility. (N Engl J Med 1997;336:410-5.)

©1997, Massachusetts Medical Society.

**M**EN with idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome (idiopathic hypogonadotropic hypogonadism and anosmia) have severe gonadotropin-releasing hormone (GnRH) deficiency.<sup>1,2</sup> Typically, men with either form of isolated GnRH deficiency have no pubertal development and respond to treatment with exogenous, pulsatile GnRH, thus localizing their defect to the hypothalamus rather than the pituitary.<sup>2-4</sup> There are variations in both the severity and time of onset of GnRH deficiency.<sup>5-7</sup> Classic isolated GnRH deficiency (Kall-

mann's syndrome and idiopathic hypogonadotropic hypogonadism) is congenital. When the presentation includes cryptorchidism and microphallus, GnRH secretion is presumed to have been absent during mid-gestation.<sup>8</sup> A less well characterized group includes men who had an age-appropriate, normal puberty but in whom GnRH deficiency subsequently developed without an identifiable cause.

This study was done to characterize the clinical and biochemical features of this latter group. Because sexual dysfunction and decreased libido are symptoms that often escape medical attention, the men we studied had symptomatic hypogonadism for many years before diagnosis. In half of them the disease was ultimately identified only through infertility evaluations, despite prior reports of impotence, loss of strength, and fatigue. A greater awareness of this syndrome may lead to earlier diagnosis and treatment.

### METHODS

#### Study Subjects

##### *Men with Adult-Onset Idiopathic Hypogonadotropic Hypogonadism*

We studied 10 men (age, 27 to 57 years) given a diagnosis of adult-onset idiopathic hypogonadotropic hypogonadism on the basis of the following: completion of puberty by the age of 18 years; presence of erectile function and ejaculation or nocturnal emissions; appearance of facial hair and libido; subsequent development of hypogonadism, including loss of sexual function, decreased libido, or infertility; repeated serum testosterone values below 100 ng per deciliter (3.47 nmol per liter) accompanied by low or normal serum luteinizing hormone and follicle-stimulating hormone concentrations; normal serum ferritin concentrations; normal base-line serum thyroxine concentrations and normal responses of serum thyrotropin, prolactin, growth hormone, and cortisol to thyrotropin-releasing hormone and insulin-induced hypoglycemia; normal findings on radiographic imaging of the hypothalamic-pituitary region; and an apulsatile pattern of luteinizing hormone secretion. These men were identified from a group of over 150 men referred to the Reproductive Endocrine Unit at Massachusetts General Hospital for evaluation of hypogonadotropic hypogonadism. Because *Kal* gene mutations are rare in men with the sporadic form of Kallmann's syndrome,<sup>9</sup> the probability of finding such a mutation in a man with adult-onset hypogonadotropic hypogonadism is very low. Therefore, the men were not tested for mutations of the *Kal* gene.

From the Reproductive Endocrine Unit and National Center for Infertility Research, Massachusetts General Hospital, Boston (L.B.N., P.A.B., W.F.C.), and the Division of Endocrinology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (F.P.P.). Address reprint requests to Dr. Crowley at the Reproductive Endocrine Unit, BHX-5, Massachusetts General Hospital, Fruit St., Boston, MA 02114.

**Men with Classic GnRH Deficiency**

Twenty-four men (age, 18 to 58 years) who repeatedly had serum testosterone values below 100 ng per deciliter (3.47 nmol per liter) accompanied by low or normal serum luteinizing hormone and follicle-stimulating hormone concentrations; normal serum ferritin concentrations; normal base-line serum thyroxine concentrations and normal responses of serum thyrotropin, prolactin, growth hormone, and cortisol to thyrotropin-releasing hormone and insulin-induced hypoglycemia; normal findings on radiographic imaging of the hypothalamic-pituitary region; and an apulsatile pattern of luteinizing hormone secretion, but who had no evidence of spontaneous pubertal development were classified as having classic GnRH deficiency and served as one control group. The results of detailed biochemical studies in these men have been reported previously.<sup>4,7</sup>

**Normal Men**

Twenty-nine normal men (age, 18 to 37 years) who met previously described selection criteria<sup>7</sup> provided normative data for serum reproductive hormone concentrations.

All studies were approved by the Human Studies Committee of Massachusetts General Hospital. All men provided informed consent for these studies and for the administration of GnRH.

**Protocol**

Testicular volume was measured with a Prader orchidometer. Serum luteinizing hormone and follicle-stimulating hormone were measured in blood samples obtained every 10 minutes for a period of 12 to 24 hours. Serum testosterone, inhibin B, and estradiol were measured in pooled aliquots of equal volumes of these samples. All hormones were measured as previously described.<sup>10-12</sup>

GnRH was synthesized at the Salk Institute and made available by the Contraceptive Development Branch, Center for Population Research, National Institute of Child Health and Human Development. GnRH was administered subcutaneously by a portable mini-infusion pump every two hours for at least six months in 5 of the men with adult-onset idiopathic hypogonadotropic hypogonadism and all 24 of the men with classic GnRH deficiency. The doses were individualized to maintain serum luteinizing hormone concentrations in the mid-normal range for men, as previously described.<sup>4</sup> Three men with adult-onset disease received

GnRH for less than three months, and the other two men in the group did not receive GnRH. One received treatment with human chorionic gonadotropin, and the other with testosterone. During the period of GnRH administration, serum luteinizing hormone, follicle-stimulating hormone, and testosterone were measured at least once a month in pooled serum from blood samples obtained at 10-minute intervals for 2 to 12 hours, and semen analyses were performed periodically.

**Statistical Analysis**

When the values were distributed normally, data for the three groups were compared by two-tailed t-tests. When the values were not distributed normally, nonparametric analysis was used. The results are expressed as means ±SD unless otherwise stated.

**RESULTS**

**Base-Line Characteristics**

The mean (±SD) age of the 10 men with adult-onset hypogonadotropic hypogonadism at presentation was 35±10 years (Table 1), and their symptoms had been present for a mean of 5±4 years (range, 1 to 11). The presenting symptoms were decreased libido, impotence, and idiopathic infertility (Table 1). Four men reported previous paternity, and none had a history of tumor, exposure to radiation, infection, or infiltrative disease involving the pituitary or hypothalamic regions. All had normal body-mass-index values, dietary habits, and exercise patterns. Their histories of head trauma, prior medical illness, psychiatric disorders, medication use, alcohol abuse, and illicit-drug use, although of unclear importance, are summarized in Table 1. All had a normal sense of smell. None had features associated with congenital GnRH deficiency (midline facial defects, synkinesis, or a family history of GnRH deficiency or anosmia).<sup>13</sup> Six men had no cranial abnormalities on computed to-

**TABLE 1.** CLINICAL AND RADIOGRAPHIC CHARACTERISTICS OF 10 MEN WITH ADULT-ONSET HYPOGONADOTROPIC HYPOGONADISM.

| PATIENT NO. | CHIEF SYMPTOM AT PRESENTATION  | AGE AT DIAGNOSIS (YR) | PRIOR PATERNITY | MEDICAL HISTORY                          | USE OF MEDICATIONS, ALCOHOL, AND ILLICIT DRUGS | CRANIAL-IMAGING FINDINGS* | RESPONSE TO PULSATILE GnRH |
|-------------|--------------------------------|-----------------------|-----------------|--|--|---------------------------|----------------------------|
| 1           | Infertility                    | 33                    | Yes             | Head trauma, left orchiectomy            | —  | Partially empty sella     | Positive                   |
| 2           | Infertility                    | 27                    | No              | Motor vehicle accident (no head trauma)  | —  | —                         | Positive                   |
| 3           | Loss of libido                 | 38                    | No              | —  | Marijuana                                      | —                         | Positive                   |
| 4           | Infertility                    | 29                    | No              | —  | Alcohol abuse (until 2 yr before study)        | Partially empty sella     | Positive                   |
| 5           | Infertility                    | 28                    | No              | —  | —  | Partially empty sella     | Positive                   |
| 6           | Loss of libido                 | 31                    | No              | —  | —  | Partially empty sella     | Positive                   |
| 7           | Impotence                      | 29                    | Yes             | Mumps orchitis, transient limb paralysis | Antihistamines                                 | —                         | Positive                   |
| 8           | Loss of libido                 | 57                    | Yes             | Depression                               | Alcohol abuse (until 10 yr before study)       | —                         | None                       |
| 9           | Loss of libido                 | 35                    | Yes             | Depression                               | Alprazolam, trazodone                          | —                         | Not tested                 |
| 10          | Infertility and loss of libido | 47                    | No              | —  | —  | —                         | Not tested                 |

\*Computed tomography or magnetic resonance imaging was performed.

mography or magnetic resonance imaging. Cranial imaging revealed a partially empty sella turcica in the remaining four men (Table 1) and no evidence of an absent or malformed olfactory system, but detailed images of the olfactory region were not done.

Base-line testicular volume in the 10 men ( $18 \pm 5$  ml), although smaller than normal, was within the range for normal men and significantly greater than in the men with classic GnRH deficiency (Table 2). All three men who could provide semen specimens were azoospermic. The mean base-line serum luteinizing hormone and follicle-stimulating hormone concentrations in the 10 men were  $1.5 \pm 1.2$  and  $2.9 \pm 1.7$  IU per liter, respectively, values similar to those in men with classic GnRH deficiency and significantly lower than those in normal men (Table 2), and their secretion of luteinizing hormone was not pulsatile (Fig. 1). Their mean serum testos-

terone concentrations were slightly but significantly higher than in the men with classic GnRH deficiency ( $78 \pm 34$  vs.  $49 \pm 20$  ng per deciliter [ $2.7 \pm 1.2$  vs.  $1.7 \pm 0.7$  nmol per liter],  $P = 0.004$ ) (Table 2). Their mean serum inhibin B concentrations (an indicator of testicular maturity<sup>12</sup>), although lower than normal, were significantly higher than in the men with classic GnRH deficiency (Table 2). Their serum estradiol concentrations were normal ( $24 \pm 3$  pg per milliliter [ $89 \pm 11$  pmol per liter]), as were their serum prolactin concentrations (range, 3 to 10 ng per milliliter; normal range, 0 to 15).

One man (Patient 10) had undergone two evaluations of reproductive function before therapy. He was first seen for idiopathic infertility at the age of 43 years, at which time his serum gonadotropin and testosterone concentrations were normal and he had a normal pattern of pulsatile luteinizing hormone


**TABLE 2.** HORMONE CONCENTRATIONS IN MEN WITH ADULT-ONSET HYPOGONADOTROPIC HYPOGONADISM OR CLASSIC GnRH DEFICIENCY AT BASE LINE AND DURING LONG-TERM ADMINISTRATION OF GnRH.\*

| GROUP AND PATIENT NO.  | BASE LINE          |                            |               |               |                     |                 | LONG-TERM GnRH THERAPY |                            |                |                 |                     |
|--|--------------------|----------------------------|---------------|---------------|---------------------|-----------------|------------------------|----------------------------|----------------|-----------------|---------------------|
|  | TESTICULAR VOLUME† | SPERM COUNT                | SERUM LH      | SERUM FSH     | SERUM TESTOSTERONE‡ | SERUM INHIBIN B | TESTICULAR VOLUME†     | SPERM COUNT                | SERUM LH       | SERUM FSH       | SERUM TESTOSTERONE‡ |
|  | ml                 | $\times 10^{-6}/\text{ml}$ | IU/liter      |               | ng/dl               | pg/ml           | ml                     | $\times 10^{-6}/\text{ml}$ | IU/liter       |                 | ng/dl               |
| <b>Men with adult-onset hypogonadotropic hypogonadism</b>        |                    |                            |               |               |                     |                 |                        |                            |                |                 |                     |
| 1  | 20                 | ND                         | 2.9           | 5.7           | 34                  | 78              | 25                     | 83                         | 10.5           | 29              | 339                 |
| 2  | 20                 | 0.0                        | 0.8           | 1             | 45                  | 80              | 20                     | 4.1                        | 22.1           | 7.4             | 371                 |
| 3  | 12.5               | 0.0                        | 0.8           | 1.9           | 118                 | 63              | 23                     | 29                         | 4.1            | 10.2            | 564                 |
| 4  | 25                 | ND                         | 0.8           | 2.2           | 100                 | 147             | 25                     | 126                        | 13             | 5               | 621                 |
| 5  | 20                 | 0.0                        | 1.6           | 1.8           | 63                  | 228             | 25                     | 35                         | 5.9            | 4.4             | 449                 |
| 6  | 14                 | ND                         | 0.8           | 2.1           | 43                  | 149             | NA                     | NA                         | NA             | NA              | NA                  |
| 7  | 20                 | ND                         | 0.8           | 1.1           | 57                  | 146             | NA                     | NA                         | NA             | NA              | NA                  |
| 8  | 23                 | ND                         | 4.3           | 4.9           | 129                 | 124             | NA                     | NA                         | NA             | NA              | NA                  |
| 9  | 12                 | ND                         | 0.8           | 2.9           | 106                 | 114             | NA                     | NA                         | NA             | NA              | NA                  |
| 10   | 9                  | ND                         | 1.8           | 4.9           | 84                  | 60              | NA                     | NA                         | NA             | NA              | NA                  |
| Mean $\pm$ SD  | $18 \pm 5$         | 0.0                        | $1.5 \pm 1.2$ | $2.9 \pm 1.7$ | $78 \pm 34$         | $119 \pm 52$    | $24 \pm 2$             | $55 \pm 49$                | $11.1 \pm 7.1$ | $11.2 \pm 10.2$ | $469 \pm 121$       |
| P value for the comparison with normal men                       | 0.03               |                            | <0.001        | <0.001        | <0.001              | <0.001          |                        |                            |                |                 |                     |
| P value for the comparison with men with classic GnRH deficiency | <0.001             |                            |               |               | 0.004               | <0.001          | <0.001                 |                            |                |                 |                     |
| <b>Men with classic GnRH deficiency (n = 24)</b>                 |                    |                            |               |               |                     |                 |                        |                            |                |                 |                     |
|  | $3 \pm 2$          | ND                         | $1.6 \pm 1.2$ | $2.4 \pm 1.2$ | $49 \pm 20$         | $60 \pm 21$     | $15 \pm 4$             | $34 \pm 75$                | $14.0 \pm 5.7$ | $10.2 \pm 3.8$  | $518 \pm 127$       |
| P value for the comparison with normal men                       |                    |                            | <0.001        | 0.002         | <0.001              | <0.001          | <0.001                 |                            |                |                 |                     |
| <b>Normal men (n = 29)</b>                                       |                    |                            |               |               |                     |                 |                        |                            |                |                 |                     |
|  | 15–25              | 25–70                      | 4.7–18.4      | 1.6–15.7      | 318–739             | 87–361          | NA                     | NA                         | NA             | NA              | NA                  |

\*LH denotes luteinizing hormone, FSH follicle-stimulating hormone, ND not done, and NA not applicable (Patients 6 through 10 received no or only short-term GnRH therapy). Plus-minus values are means  $\pm$ SD. Values for the normal men are ranges.

†Values are the mean of right and left testicular volumes except in Patient 1, in whom the volume of a single (right) testis is given.

‡To convert values for serum testosterone to nanomoles per liter, multiply by 0.0347.



**Figure 1.** Representative 24-Hour Patterns of Luteinizing Hormone Secretion in a Normal Man and Three Men with Adult-Onset Hypogonadotropic Hypogonadism.

The shaded areas represent the mean ( $\pm 2$  SD) values in 29 normal men. To convert values for serum testosterone to nanomoles per liter, multiply by 0.0347. LH denotes luteinizing hormone, and FSH follicle-stimulating hormone.

secretion (Fig. 2). He returned four years later because of additional symptoms of decreased libido and sexual dysfunction, at which time he had apulsatile luteinizing hormone secretion (Fig. 2).


#### Response to Pulsatile GnRH Therapy

Seven of the eight men with adult-onset idiopathic hypogonadotropic hypogonadism who received GnRH had normal serum gonadotropin and testosterone concentrations during therapy. One man (Patient 8) had no increase in serum gonadotropin and testosterone concentrations after the administration of GnRH for eight weeks. The five men who received GnRH for at least six months had serum hormonal values similar both to those of similarly treated men with classic GnRH deficiency and to those of normal men (Table 2). Spermatogenesis was restored more rapidly in the five men with acquired hypogonadotropic hypogonadism than in men with classic GnRH deficiency, with maximal sperm concentrations ( $55 \pm 49 \times 10^6$  per milliliter vs.  $34 \pm 75 \times 10^6$  per milliliter,  $P = 0.56$ ) achieved  $33 \pm 16$

and  $92 \pm 56$  weeks ( $P = 0.04$ ), respectively, after the men's serum testosterone concentrations had increased to within the normal range. In all five of these men the results of semen analyses were consistent with fertility, and all three seeking fertility (Patients 1, 2, and 4) fathered a child. The remaining five men chose long-term treatment with either testosterone (Patients 6, 7, 8, and 9) or human chorionic gonadotropin (Patient 10), which restored their libido and sexual function. In Patients 8 and 9, depression did not resolve during testosterone therapy. The men with adult-onset idiopathic hypogonadotropic hypogonadism continued to require treatment for hypogonadal symptoms throughout follow-up (duration,  $7 \pm 5$  years; range, 2 to 16).

#### DISCUSSION

We have described a group of men with adult-onset idiopathic hypogonadotropic hypogonadism who had no recognizable central nervous system abnormalities. In considering this disorder, several questions should be addressed. First, was the defect



**Figure 2.** Serial Studies of Luteinizing Hormone Secretion in a Man with Adult-Onset Hypogonadotropic Hypogonadism.

At the time of the second evaluation the patient had symptoms of hypogonadism. The shaded areas represent the mean ( $\pm 2$  SD) values in 29 normal men. To convert values for serum testosterone to nanomoles per liter, multiply by 0.0347. LH denotes luteinizing hormone, and FSH follicle-stimulating hormone.

acquired? Second, were anatomical and functional causes properly excluded? Third, what is the level of the defect?

The normal spontaneous sexual maturation in these men and the documented fertility in several before the onset of their reproductive dysfunction are strong evidence that the defect is acquired. Furthermore, the results of serial studies in one man provide documentation of the development of GnRH deficiency. Thus, both the clinical and biochemical manifestations of adult-onset hypogonadotropic hypogonadism appear to be acquired.

The anatomical causes of acquired hypogonadotropic hypogonadism encompass a large range of disorders, including infiltrative processes and space-occupying lesions such as hemochromatosis,<sup>14</sup> pituitary adenomas and other tumors,<sup>15-17</sup> granulomatous disease,<sup>18-20</sup> and lymphocytic hypophysitis.<sup>21</sup> Hemochromatosis, the disease most likely to cause acquired isolated gonadotropin deficiency in relatively young men, was ruled out by the presence of normal serum ferritin concentrations, and in addition, responsiveness to GnRH is poor in men with hemochromatosis, because of the predominantly pituitary defect in gonadotropin secretion.<sup>22</sup> The importance of the finding of a partially empty sella turcica in 4 of the 10 men is uncertain; about 20 percent of normal subjects have an empty sella without an associated clinical syndrome.<sup>23</sup> One of the men with adult-onset hypogonadotropic hypogonadism had a history of head trauma. However, hypogonadotropic hypogonadism

associated with head trauma is usually transient, occurring in the setting of severe traumatic coma associated with concomitant deficiencies of thyroid and adrenal function.<sup>24-26</sup>

In addition to anatomical disorders, psychogenic stress, medical illness, excessive exercise, and malnutrition are known to cause isolated GnRH deficiency in women.<sup>27</sup> It is possible that adult-onset hypogonadotropic hypogonadism as described here is the male counterpart of hypothalamic amenorrhea. Some of these men were depressed or had histories of alcohol or drug abuse, but these disorders are rarely associated with prolonged hypoandrogenemia as severe as in the men we studied.<sup>28</sup> Men with acute medical illness may have substantial transient decreases in serum testosterone and gonadotropin concentrations,<sup>29</sup> but the men we studied were not acutely ill. They were also not exercising excessively or starving themselves, each of which can cause decreased serum testosterone concentrations.<sup>30,31</sup> Thus, neither an anatomical nor a known functional cause of hypogonadism was identified in the men we studied.

Although the severity of other acquired forms of GnRH deficiency (anatomical or functional) varies, the absence of pulsatile luteinizing hormone secretion in these men suggests severe GnRH deficiency. However, their base-line serum testosterone concentrations, although low, were significantly higher than in men with classic GnRH deficiency. This residual Leydig-cell function could reflect minimal residual luteinizing hormone secretion, only detectable with

supersensitive assays,<sup>32</sup> or the post-pubertal nature of their gonadotropin deficiency.

The nearly uniform responsiveness to pulsatile GnRH administration localizes the functional defect in these men to the parvocellular GnRH neuronal system within the hypothalamus. The cause may be defective biosynthesis or secretion of GnRH. Acquired defects of an autoimmune or toxicologic nature resulting in selective destruction of neuromodulators of GnRH secretion within the arcuate-nucleus region of the hypothalamus thus remain a possibility. Autoimmune pituitary disease causing isolated hypogonadotropic hypogonadism is rare in men<sup>21</sup> and would not account for the response of most of our subjects to exogenous GnRH administration. Selective and presumably cell-specific autoimmune destruction of a subgroup of hypothalamic neurons has yet to be described. Finally, it is possible that despite its post-pubertal presentation, adult-onset hypogonadotropic hypogonadism results from the delayed onset of a dominant genetic defect of GnRH secretion, similar to the latent manifestations of familial neurohypophysial diabetes insipidus, a rare autosomal dominant disorder associated with deficiency of arginine vasopressin.<sup>33</sup> The absence of affected relatives suggests that if there is a genetic cause of this syndrome, the cases described are sporadic.

Although its cause is obscure, adult-onset hypogonadotropic hypogonadism is a unique form of isolated hypogonadotropic hypogonadism arising in sexually mature men. The clinical recognition of this syndrome is important, since it represents one of the few treatable forms of male infertility.

Supported in part by grants from the National Institutes of Health (R01-HD-15788), the National Center Program for Infertility Research (U54-HD29164), the Reproductive Endocrine Sciences Center (P30-HD28138), and the General Clinical Research Center (RR 01066) at Massachusetts General Hospital and Harvard Medical School and by a contract (NO1-HD-2906) with the National Institutes of Health.

*We are indebted to our research assistant, Mrs. Amy E. LeCain; to the staff of our Clinical Research Unit; to the technicians of the Reproductive Endocrine Sciences Center's Radioimmunoassay Core Laboratory; and to Jean Rivier, Ph.D., and Marvin Karten, Ph.D., for their continued support.*

## REFERENCES

- Kallmann FJ, Schoenfeld, WA, Barerra SE. The genetic aspects of primary eunuchoidism. *Am J Ment Defic* 1944;48:203-36.
- Valk TW, Corley KP, Kelch RP, Marshall JC. Hypogonadotropic hypogonadism: hormonal responses to low dose pulsatile administration of gonadotropin-releasing hormone. *J Clin Endocrinol Metab* 1980;51:730-8.
- Hoffman AR, Crowley WF Jr. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. *N Engl J Med* 1982;307:1237-41.
- Spratt DI, Finkelstein JS, O'Dea LS, et al. Long-term administration of gonadotropin-releasing hormone in men with idiopathic hypogonadotropic hypogonadism: a model for studies of the hormone's physiologic effects. *Ann Intern Med* 1986;105:848-55.
- Barkan AL, Reame NE, Kelch RP, Marshall JC. Idiopathic hypogonadotropic hypogonadism in men: dependence of the hormone responses to gonadotropin-releasing hormone (GnRH) on the magnitude of the endogenous GnRH secretory defect. *J Clin Endocrinol Metab* 1985;61:1118-25.
- Spitz IM, Diamant Y, Rosen E, et al. Isolated gonadotropin deficiency: a heterogeneous syndrome. *N Engl J Med* 1974;290:10-5.
- Spratt DI, Carr DB, Merriam GR, Scully RE, Rao PN, Crowley WF Jr. The spectrum of abnormal patterns of gonadotropin-releasing hormone secretion in men with idiopathic hypogonadotropic hypogonadism: clinical and laboratory correlations. *J Clin Endocrinol Metab* 1987;64:283-91.
- Santen RJ, Paulsen CA. Hypogonadotropic eunuchoidism. I. Clinical study of the mode of inheritance. *J Clin Endocrinol Metab* 1973;36:47-54.
- Georgopoulos N, Pralong FP, Seidman CE, Seidman JG, Crowley WF, Vallejo M. Low incidence of Kal-1 mutations in sporadic cases of gonadotropin releasing hormone (GnRH) deficiency: evidence for the existence of autosomal genes involved in GnRH expression. *J Clin Endocrinol Metab* 1997;82:213-7.
- Filicori M, Butler JP, Crowley WF Jr. Neuroendocrine regulation of the corpus luteum in the human: evidence for pulsatile progesterone secretion. *J Clin Invest* 1984;73:1638-47.
- Narasimha Rao P, Moore PH Jr. Synthesis of new steroid haptens for radioimmunoassay. I. 15 $\beta$ -Carboxyethylmercaptotestosterone-bovine serum albumin conjugate: measurement of testosterone in male plasma without chromatography. *Steroids* 1976;28:101-9.
- Nachtigall LB, Boepple PA, Seminara SB, et al. Inhibin B secretion in males with gonadotropin-releasing hormone (GnRH) deficiency before and during long-term GnRH replacement: relationship to spontaneous puberty, testicular volume, and prior treatment — a clinical research center study. *J Clin Endocrinol Metab* 1996;81:3520-5.
- Waldsreicher J, Seminara SB, Jameson LJ, et al. The genetic and clinical heterogeneity of gonadotropin releasing hormone (GnRH) deficiency in the human. *J Clin Endocrinol Metab* 1996;81:4388-95.
- Charbonnel B, Chupin M, Le Grand A, Guillon J. Pituitary function in idiopathic haemochromatosis: hormonal study in 36 male patients. *Acta Endocrinol* 1981;98:178-83.
- Snyder PJ. Gonadotroph cell pituitary adenomas. *Endocrinol Metab Clin North Am* 1987;16:755-64.
- Jenkins JS, Gilbert CJ, Ang V. Hypothalamic-pituitary function in patients with craniopharyngiomas. *J Clin Endocrinol Metab* 1976;43:394-9.
- Takeuchi J, Handa H, Nagata I. Suprasellar germinoma. *J Neurosurg* 1978;49:41-8.
- Braunstein GD, Kohler PO. Endocrine manifestations of histiocytosis. *Am J Pediatr Hematol Oncol* 1981;3:67-75.
- Ranjan A, Chandy MJ. Intracellar tuberculoma. *Br J Neurosurg* 1994;8:179-85.
- Cariski AT. Isolated CNS sarcoidosis. *JAMA* 1981;245:62-3.
- Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S. Lymphocytic hypophysitis: clinicopathological findings. *J Clin Endocrinol Metab* 1995;80:2302-11.
- Duranteau L, Chanson P, Blumberg-Tick J, et al. Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect. *Acta Endocrinol* 1993;128:351-4.
- Hardjasudarma M, White KE, Nandy I, Burns PL. Sellar emptiness on routine magnetic resonance imaging. *South Med J* 1994;87:340-3.
- Paxson CL, Brown DR. Post-traumatic hypopituitarism. *Pediatrics* 1976;57:893-96.
- Rudman D, Fleischer AS, Kutner MH, Raggio JF. Suprahypophysial hypogonadism and hypothyroidism during prolonged coma after head trauma. *J Clin Endocrinol Metab* 1977;45:747-54.
- Fok AC, Tsakok FH, Sum CE, Cheah JS. Restoration of spermatogenesis with pulsatile gonadotrophin releasing hormone therapy in hypogonadotropic hypogonadism of traumatic etiology. *Aust N Z J Med* 1989;19:354-7.
- Yen SS. Female hypogonadotropic hypogonadism: hypothalamic amenorrhea syndrome. *Endocrinol Metab Clin North Am* 1993;22:29-58.
- Van Thiel DH, Lester R, Sherins RJ. Hypogonadism in alcoholic liver disease: evidence for a double defect. *Gastroenterology* 1974;67:1188-99.
- Woolf PD, Hamill RW, McDonald JV, Lee LA, Kelly M. Transient hypogonadotropic hypogonadism caused by critical illness. *J Clin Endocrinol Metab* 1985;60:444-50.
- Cameron JL, Weltzin TE, McConaha C, Helmreich DL, Kaye WH. Slowing of pulsatile luteinizing hormone secretion in men after forty-eight hours of fasting. *J Clin Endocrinol Metab* 1991;73:35-41.
- Roberts AC, McClure RD, Weiner RI, Brooks GA. Overtraining affects male reproductive status. *Fertil Steril* 1993;60:686-92.
- Wu FCW, Butler GE, Kelnar CJH, Sellar ME. Patterns of pulsatile luteinizing hormone secretion before and during the onset of puberty in boys: a study using an immunoradiometric assay. *J Clin Endocrinol Metab* 1990;70:629-37.
- McLeod JF, Kovacs L, Gaskill MB, Rittig S, Bradley GS, Robertson GL. Familial neurohypophysial diabetes insipidus associated with a signal peptide mutation. *J Clin Endocrinol Metab* 1993;77:599A-599G.